Botensilimab/Balstilimab Data in Neoadjuvant Colorectal Cancer Selected for ASCO-GI 2024
2023年12月20日 - 9:30PM
ビジネスワイヤ(英語)
Agenus Inc. (“Agenus”) (Nasdaq: AGEN), a leader in discovering
and developing novel immunological agents to treat various cancers,
today announced that data from an investigator sponsored trial
(IST) evaluating botensilimab (BOT, multifunctional CTLA-4 immune
activator) in combination with balstilimab (BAL, PD-1 antibody) in
neoadjuvant colorectal cancer (CRC) will be presented at the
upcoming ASCO-GI Meeting, to be held January 18 – 20, 2024 in San
Francisco, CA. The IST is led by Pashtoon Kasi, M.D., who was
recruited to Weill Cornell Medicine as an associate professor of
medicine and is a member of its Sandra and Edward Meyer Cancer
Center. Dr. Kasi is also an oncologist at NewYork
Presbyterian/Weill Cornell Medical Center.
Presentation Details:
Abstract Title: Neoadjuvant botensilimab plus balstilimab
in resectable mismatch repair proficient and deficient colorectal
cancer: NEST-1 clinical trial (NCT05571293) Abstract Number:
117 Presenting Author: Pashtoon Kasi, M.D., M.S., Director
of Colon Cancer Research at Weill Cornell Medicine/NewYork
Presbyterian Hospital, and Director of Liquid Biopsy Research,
Englander Institute of Precision Medicine, Sarah and Edward Meyer
Center Session: Poster Session C: Cancers of the Colon,
Rectum, and Anus Presentation Date and Time: 1/20/2024,
6:30am – 7:55am EST
Complete abstracts will be released on Tuesday, January 16, 2024
at 5:00pm EST. Data presented at the conference will be available
to view in the publications section of the Agenus website
(https://agenusbio.com/publications) following the ASCO-GI
Meeting.
About Botensilimab
Botensilimab is an investigational multifunctional anti-CTLA-4
immune activator (antibody) designed to boost both innate and
adaptive anti-tumor immune responses. Its novel design leverages
mechanisms of action to extend immunotherapy benefits to "cold"
tumors which generally respond poorly to standard of care or are
refractory to conventional PD-1/CTLA-4 therapies and
investigational therapies. Botensilimab augments immune responses
across a wide range of tumor types by priming and activating T
cells, downregulating intratumoral regulatory T cells, activating
myeloid cells and inducing long-term memory responses.
Approximately 750 patients have been treated with botensilimab
in phase 1 and phase 2 clinical trials. Botensilimab alone, or in
combination with Agenus’ investigational PD-1 antibody,
balstilimab, has shown clinical responses across nine metastatic,
late-line cancers. For more information about botensilimab trials,
visit www.clinicaltrials.gov with the identifiers NCT03860272,
NCT05608044, NCT05630183, and NCT05529316.
About Agenus
Agenus is a leading immuno-oncology company targeting cancer and
infectious diseases with a comprehensive pipeline of immunological
agents. The company’s mission is to expand patient populations
benefiting from cancer immunotherapy through combination
approaches, using a broad repertoire of antibody therapeutics,
adoptive cell therapies (through MiNK Therapeutics) and adjuvants
(through SaponiQx). Agenus is headquartered in Lexington, MA. For
more information, visit www.agenusbio.com or @agenus_bio.
Information that may be important to investors will be routinely
posted on our website and social media channels.
Forward Looking
Statements
This press release contains forward-looking statements that are
made pursuant to the safe harbor provisions of the federal
securities laws, including statements relating to the use of
botensilimab and balstilimab, for instance, statements regarding
therapeutic benefit and efficacy, mechanism of action (including
validation of mechanism of action), potency, durability, and safety
profile (including the absence of specific toxicities) of the
Company’s therapeutic candidates; and any other statements
containing the words "may," "believes," "expects," "anticipates,"
"hopes," "intends," "plans," "forecasts," "estimates," "will,"
“establish,” “potential,” “superiority,” “best in class,” and
similar expressions are intended to identify forward-looking
statements. These forward-looking statements are subject to risks
and uncertainties that could cause actual results to differ
materially. These risks and uncertainties include, among others,
the factors described under the Risk Factors section of our most
recent Quarterly Report on Form 10-Q or Annual Report on Form 10-K
filed with the Securities and Exchange Commission. Agenus cautions
investors not to place considerable reliance on the forward-looking
statements contained in this release. These statements speak only
as of the date of this press release, and Agenus undertakes no
obligation to update or revise the statements, other than to the
extent required by law. All forward-looking statements are
expressly qualified in their entirety by this cautionary
statement.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20231220565677/en/
Investors 917-362-1370 investor@agenusbio.com
Media 781-674-4784 communications@agenusbio.com
Agenus (NASDAQ:AGEN)
過去 株価チャート
から 4 2024 まで 5 2024
Agenus (NASDAQ:AGEN)
過去 株価チャート
から 5 2023 まで 5 2024